2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.09 Efficacy and Safety of Neoadjuvant Tislelizumab Plus Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: a Pooled Analysis

EP.08D.09 Efficacy and Safety of Neoadjuvant Tislelizumab Plus Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: a Pooled Analysis

Back to course

Pdf Summary

This document presents a pooled meta-analysis assessing the efficacy and safety of neoadjuvant tislelizumab combined with chemotherapy for treating non-small cell lung cancer (NSCLC). Tislelizumab is an immune checkpoint inhibitor, and its combination with chemotherapy is explored across various clinical studies.<br /><br />The analysis incorporated data from nine studies involving 280 patients. The main focus was on the pathological complete response (pCR), major pathological response (MPR), overall response rate (ORR), and the rate of R0 resection, alongside treatment-related adverse events (TRAEs). Key findings include a pooled pCR rate of 40%, an MPR rate of 65%, and an ORR of 76%. The studies showed a high R0 resection rate of 100%, indicating complete removal of the tumor in resected samples.<br /><br />The analysis also evaluated the safety of the treatment. The overall incidence of all-grade TRAEs was 89%, with grade 3 TRAEs (severe side effects) occurring in 17% of participants. These findings indicate that while the treatment shows considerable efficacy, there are substantial side effects that require consideration.<br /><br />The study tapped into a collection of sources, including PubMed, Embase, and proceedings from international conferences. The inclusion criteria excluded non-human studies, reviews, small-scale studies, and non-original research. Statistical analysis was performed using R software, ensuring rigorous methodological scrutiny.<br /><br />The authors concluded that the combination of tislelizumab and chemotherapy is both effective and safe for use in NSCLC patients, as evidenced by the significant pathology responses and acceptable safety profile observed across multiple clinical trials. This underlines the potential of tislelizumab as an impactful addition to NSCLC neoadjuvant therapies.

Asset Subtitle

Yao-Bin Lin

Meta Tag

Speaker Yao-Bin Lin

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

neoadjuvant tislelizumab

chemotherapy

non-small cell lung cancer

NSCLC

immune checkpoint inhibitor

pathological complete response

major pathological response

treatment-related adverse events

R0 resection

meta-analysis